Vancomycin Side Effects: Safety Signals and Warnings
Vancomycin safety concerns are compound-specific. The main listed side effects are Nephrotoxicity, Red man syndrome (infusion-related), and Ototoxicity (rare, usually at high serum levels). The main warning signals are Requires therapeutic drug monitoring (trough levels or AUC-guided dosing), Dose adjustment essential in renal impairment, and Ototoxicity risk increases with concomitant ototoxic drugs.
Direct Answer
Vancomycin is FDA-approved and remains the gold standard for MRSA treatment and serious gram-positive infections where beta-lactams are contraindicated. With decades of clinical data, well-established PK/PD targets, and consistent Phase 3 evidence, it is one of the most validated antibiotics in medicine. For gram-positive infection research, vancomycin is the reference compound.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Immune Support
- Best for
- MRSA infections, serious gram-positive infections, C. difficile colitis (oral), beta-lactam-resistant infections
Reported Side Effects
- Nephrotoxicity
- Red man syndrome (infusion-related)
- Ototoxicity (rare, usually at high serum levels)
- Thrombocytopenia
- Neutropenia (with prolonged use)
- Phlebitis at injection site
- Nausea
Warnings
- Requires therapeutic drug monitoring (trough levels or AUC-guided dosing)
- Dose adjustment essential in renal impairment
- Ototoxicity risk increases with concomitant ototoxic drugs
- Vancomycin-resistant enterococci (VRE) are an emerging clinical concern
- Infuse over at least 60 minutes to prevent red man syndrome
Known or Plausible Interactions
- Aminoglycosides (increased nephrotoxicity and ototoxicity)
- Piperacillin-tazobactam (increased risk of acute kidney injury)
- NSAIDs (may increase vancomycin levels)
- Loop diuretics (additive ototoxicity risk)
- Anesthetic agents (risk of erythema and hypotension)
Regulatory Context
FDA-approved since 1958. Prescription required. Available generically. Listed on the WHO Essential Medicines List. Available worldwide. Both IV and oral formulations are approved.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | MRSA Infection Treatment (Level A), C. difficile Infection (Oral) (Level A), Nephrotoxicity (Adverse) (Level A), and Red Man Syndrome (Adverse) (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Vancomycin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/vancomycin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.